Techsomed announced today the U.S. launch of its BioTrace software suite, including the BioTraceIO Vision and BioTraceIO Precision solutions. Both products received FDA clearance last year for liver tumor ablation and are now being deployed at medical institutions across the country
BioTraceIO Vision employs advanced AI-based technology to deliver personalized treatment planning and assessment tools, utilizing standard medical imaging to enhance the accuracy and efficiency of image-guided ablation therapy. BioTraceIO Precision, which received FDA De-Novo clearance, uses real-time ultrasound data to provide clinicians with predictive insights on post-ablation tissue damage. Importantly, both BioTraceIO Vision and BioTraceIO Precision are vendor-agnostic, seamlessly integrating with existing ablation systems and ultrasound machines to provide a streamlined workflow.
